Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP471725.RAaCmM3IqpWOTooYSDrIP-uH7Cj_cjGlaqQ_syjQc5Vu4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP471725.RAaCmM3IqpWOTooYSDrIP-uH7Cj_cjGlaqQ_syjQc5Vu4130_assertion type Assertion NP471725.RAaCmM3IqpWOTooYSDrIP-uH7Cj_cjGlaqQ_syjQc5Vu4130_head.
- NP471725.RAaCmM3IqpWOTooYSDrIP-uH7Cj_cjGlaqQ_syjQc5Vu4130_assertion description "[Chronic exposure to high levels of 5-HT (from metastatic carcinoid tumours), the anorectic drug fenfluramine and its metabolites, as well as the ecstasy drug 3,4-methylenedioxymethamphetamine (MDMA) and its metabolite 3,4-methylenedioxyamphetamine (MDA) are associated with proliferative disease and thickening of cardiac valves, mediated through 5-HT2B receptors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP471725.RAaCmM3IqpWOTooYSDrIP-uH7Cj_cjGlaqQ_syjQc5Vu4130_provenance.
- NP471725.RAaCmM3IqpWOTooYSDrIP-uH7Cj_cjGlaqQ_syjQc5Vu4130_assertion evidence source_evidence_literature NP471725.RAaCmM3IqpWOTooYSDrIP-uH7Cj_cjGlaqQ_syjQc5Vu4130_provenance.
- NP471725.RAaCmM3IqpWOTooYSDrIP-uH7Cj_cjGlaqQ_syjQc5Vu4130_assertion SIO_000772 16960982 NP471725.RAaCmM3IqpWOTooYSDrIP-uH7Cj_cjGlaqQ_syjQc5Vu4130_provenance.
- NP471725.RAaCmM3IqpWOTooYSDrIP-uH7Cj_cjGlaqQ_syjQc5Vu4130_assertion wasDerivedFrom befree-20150227 NP471725.RAaCmM3IqpWOTooYSDrIP-uH7Cj_cjGlaqQ_syjQc5Vu4130_provenance.
- NP471725.RAaCmM3IqpWOTooYSDrIP-uH7Cj_cjGlaqQ_syjQc5Vu4130_assertion wasGeneratedBy ECO_0000203 NP471725.RAaCmM3IqpWOTooYSDrIP-uH7Cj_cjGlaqQ_syjQc5Vu4130_provenance.